Overview

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination

Phase:

Phase 1

Details

Lead Sponsor:

University of Utah

Collaborators:

Array BioPharma
Pfizer